CNS Drugs, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 2, 2024
Language: Английский
The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: 12(2), P. 100025 - 100025
Published: Jan. 23, 2025
Language: Английский
Citations
2
Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21
Published: Jan. 7, 2025
Introduction Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous clinical presentation rates progression. As changes occur many people with PD, it essential to evaluate cognition, provide education, implement management strategies for symptoms.
Language: Английский
Citations
1
Alzheimer s & Dementia Translational Research & Clinical Interventions, Journal Year: 2025, Volume and Issue: 11(1)
Published: Jan. 1, 2025
Language: Английский
Citations
1
JAMA, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 29, 2025
Importance The effectiveness of different approaches to dementia care is unknown. Objective To determine the health system–based, community-based care, and usual for persons with caregiver outcomes. Design, Setting, Participants Randomized clinical trial community-dwelling living their caregivers conducted at 4 sites in US (enrollment June 2019-January 2023; final follow-up, August 2023). Interventions were randomized 7:7:1 system–based provided by an advanced practice specialist (n = 1016); a social worker, nurse, or licensed therapist consultant 144). Main Outcomes Measures Primary outcomes caregiver-reported Neuropsychiatric Inventory Questionnaire (NPI-Q) severity score (range, 0-36; higher scores, greater behavioral symptoms severity; minimal clinically important difference [MCID], 2.8-3.2) Modified Caregiver Strain Index 0-26; strain; MCID, 1.5-2.3). Three secondary included self-efficacy 4-20; more self-efficacy). Results Among 2176 dyads (individuals dementia, mean age, 80.6 years; 58.4%, female; 20.6%, Black Hispanic; caregivers, 65.2 75.8%, 20.8% Hispanic), primary assessed than 99% participants, 1343 participants (62% those enrolled 91% still alive had not withdrawn) completed study through 18 months. No significant differences existed between 2 treatments vs Overall, least squares means (LSMs) NPI-Q scores 9.8 system, 9.5 community-based, 10.1 care. system was 0.30 (97.5% CI, −0.18 0.78); −0.33 −1.32 0.67); −0.62 −1.61 0.37). LSMs 10.7 10.5 10.6 0.25 −0.16 0.66); 0.14 −0.70 0.99); −0.10 −0.94 0.74). Only outcome significantly both but treatments: 15.1 15.2 14.4 (95% −0.37 0.06); 0.70 0.26-1.14); 0.85 0.42 1.29). Conclusions Relevance In this programs, no interventions nor either active intervention regarding patient strain. Trial Registration ClinicalTrials.gov Identifier: NCT03786471
Language: Английский
Citations
1
Brain and Behavior, Journal Year: 2025, Volume and Issue: 15(1)
Published: Jan. 1, 2025
ABSTRACT Background In recent years, cognitive impairment has emerged as a pivotal symptom in elderly patients with depression, exerting substantial impact on the course and prognosis of diseases. Moreover, it persists even following remission from depression during rehabilitation period. However, there remains an incomplete understanding relevant influencing factors for depressed patients, which seriously impedes development risk prediction models subsequent research precision intervention programs. Objective The purpose this study is to examine current state negative assessment tools late‐life (LLD), thereby providing theoretical framework construction targeted Methods search strategy employed followed evidence‐based approach, utilizing systematic scoping review thoroughly explore six English four Chinese databases up until November 2023. Two researchers independently conducted article screening thematic analysis categorize results into themes. Results Following two rounds rigorous by team, data were meticulously extracted succinctly summarized five distinct themes encompassing socio‐demographic, physiological, psychological, genetic, other related factors. addition, comprehensive compilation 19 diverse was undertaken. Ultimately, total 22 articles met eligibility criteria inclusion study. These comprised longitudinal studies, nine pathological controlled cross‐sectional cohort one randomized Conclusion Cognitive dysfunction important LLD, affects survival patients. At present, its mainly includes There have been existing function specifically those 18‐ 65‐year‐old major depressive disorder, but still lack reliability validity tests LLD.
Language: Английский
Citations
0
The Lancet Regional Health - Western Pacific, Journal Year: 2025, Volume and Issue: 55, P. 101465 - 101465
Published: Jan. 21, 2025
Language: Английский
Citations
0
Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 17
Published: Feb. 5, 2025
Background Insulin resistance (IR) is recognized as a potential modifiable risk factor for cognitive decline, but findings within Asian populations have been inconsistent. Given the high prevalence of dementia and its substantial economic burden in China, large-scale longitudinal studies are essential to elucidate complex relationship between IR function. Methods This cohort study included 8,734 middle-aged older adults (median age: 58 years; 53.6% females) from China Health Retirement Longitudinal Study (CHARLS), followed 2011 2018. Estimated glucose disposal rate (eGDR) was used assess calculated using waist circumference, hypertension status, HbA1c levels. Participants were categorized into tertiles based on eGDR levels (Tertile 1: lowest; Tertile 3: highest). Cognitive function sum episodic memory executive scores, which then standardized Z -score. Linear mixed-effects models dose-response analyses performed evaluate association baseline changes total population stratified by sex. Results Higher significantly associated with slower global decline 3 vs. β = 0.007; 95% CI: 0.000–0.014; P 0.047). stronger females 0.011; 0.002–0.021; 0.021), while no significant observed males. Dose-response indicated linear positive females, not Similar patterns found function, associations predominantly females. Conclusion particularly among women. These underscore marker identifying mitigating highlight importance sex-specific strategies address insulin promote health.
Language: Английский
Citations
0
Toxicology Reports, Journal Year: 2025, Volume and Issue: 14, P. 101958 - 101958
Published: Feb. 10, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1634 - 1634
Published: Feb. 14, 2025
Aging and age-related neurodegenerative disorders are characterized by the dysfunction or loss of brain nicotinic acetylcholine receptors (nAChRs), these changes may be related to other senescence markers, such as oxidative stress DNA repair dysfunction. However, mechanism nAChR in aging modification this process drugs (e.g., memantine, Mem) not yet fully understood. To study whether differences expression rat occur due modulated Mem, we analyzed subunits (at RNA protein levels) biomarkers real-time quantitative polymerase chain reaction (RQ-PCR) Western blot validation. Twenty-one female Wistar rats were divided into four groups, depending on age, oldest group received injections Mem water with use intragastric catheters. We studied cerebral grey matter (CGM), subcortical white (SCWM), cerebellum (Ce). Results showed an decrease α7 mRNA level SCWM. The was accompanied reduced 8-oxoguanine glycosylase 1 (OGG1) increased tumor necrosis factor alpha (TNFα) level. In group, observed a higher SCWM Ce. Biomarker levels changed, but different extent area. Importantly, antioxidative status stopped even regressed under treatment. After two weeks treatment, increase TP53 8-oxo-2'deoxyguanosine (8-oxo-2'dG) observed. conclude that administration protective against mechanisms.
Language: Английский
Citations
0
Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0
Published: Jan. 1, 2025
Cerebral small vessel disease (CSVD) is a common in older people, characterized by damage to intracranial microvessels, leading cognitive decline, increased risk of stroke, and dementia. This review reviews the current therapeutic approaches for CSVD latest research advances, encompassing traditional pharmacological therapies, emerging targeted interventions grounded pathophysiology, exploratory immune-related treatments, advances genetic research. In addition, role lifestyle modifications management discussed. The emphasizes importance holistic, personalized treatment strategy improve outcomes. More clinical trials are needed validate these treatments optimize individualized options patients.
Language: Английский
Citations
0